Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. November 2025 08:00 ET | Quelle: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases

Imbria extends Series B financing with new investor AXA IM Alts to advance ninerafaxstat and address urgent global cardiovascular health challenges.
06. November 2025 08:00 ET | Quelle: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals announces first patient randomized in Phase 2b FORTITUDE-HCM trial of ninerafaxstat for non-obstructive hypertrophic cardiomyopathy.
16. September 2025 08:00 ET | Quelle: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments

Imbria Pharmaceuticals Strengthens Leadership, Appoints Dr. Cheruvu as Board Chair; James Januzzi, MD, as Senior Research Advisor and SAB Chair.
15. September 2022 08:00 ET | Quelle: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
22. August 2022 08:00 ET | Quelle: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today...